Clinical trials: Finerenone
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access.
- Trial name
- IN-REALITY (NCT06763146)
- Testing
- Finerenone (Kerendia, BAY948862)
- Where
- India
- Volunteers
- 1,200 people
- Sponsor
- Bayer
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a long-term, progressive decrease in the kidneys' ability to work properly.
- Trial name
- FIGARO-BM (NCT05013008)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 115 sites in United States, Australia and 19 more
- Volunteers
- 951 people
- Sponsor
- Bayer
CKD - Chronic Kidney Disease, Diabetes Mellitus Type 2
Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
The goal of this study, performed entirely with computer programs, is to learn if using a combination of two drugs works better than using one alone, in the treatment of people with chronic kidney disease and type 2 diabetes…
- Trial name
- NCT07719621
- Where
- Spain
- Volunteers
- 100,000 people
- Sponsor
- Aeterna Medical Solutions SL
Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers
A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants
In this bioequivalence study, healthy male participants took the study treatment finerenone in the form of one and two tablets of different strengths by mouth.
- Trial name
- NCT07116512
- Testing
- Finerenone (BAY94-8862): intervention A, Finerenone (BAY94-8862): intervention B
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bayer
IgA Nephropathy (IgAN)
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
: IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy…
- Trial name
- NCT07056595
- Testing
- Finerenone
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Botkin Hospital
Diabetic Nephropathy
"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) is a major cause of morbidity, commonly associated with persistent albuminuria and progressive renal decline.
- Trial name
- NCT07598864
- Testing
- Dapagliflozin +Finerenone arm, Dapagliflozin arm
- Where
- Bangladesh
- Volunteers
- 88 people
- Sponsor
- Chittagong Medical College
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
Retinal Nerve Fiber Layer Thickness, Chronic Kidney Disease
Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease
Interestingly, A hypothesis-generating analysis was conducted from two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR), suggesting a potential benefit of finerenone in the…
- Trial name
- NCT07235891
- Testing
- Finerenone
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Alexandria University
Chronic Kidney Disease
FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors
Study to demonstrate efficacy of finerenone when compared to placebo in reducing albuminuria in participants with chronic kidney disease (CKD) not using renin-angiotensin-system (RAS) inhibitors.
- Trial name
- FINE-START (NCT07181135)
- Testing
- Finerenone (BAY 94-8862)
- Where
- 8 sites in Spain
- Volunteers
- 180 people
- Sponsor
- University Medical Center Groningen
Chronic Heart Failure
A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea
This is an observational study in which data from people with chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40%. who will be receiving finerenone are studied.
- Trial name
- NCT07379840
- Testing
- finerenone (BAY94-8862)
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Bayer
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD).
- Trial name
- FIORE (NCT07188805)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 133 sites in United States, Argentina and 21 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus
Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.
The global prevalence of diabetes is increasing substantially. Around 40 % of patients with type 2 diabetes develop chronic kidney disease.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Trial name
- FineCaRe (NCT07026539)
- Testing
- Finerenone (BAY 94-8862)
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University of Aarhus
Acute Heart Failure
Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure
FACILITATE-HF is a multicenter, randomized, double-blind, placebo-controlled trial designed to determine whether initiation of finerenone during the early phase of hospitalization has beneficial effects in patients with AHF who…
- Trial name
- FACILITATE-HF (NCT07397650)
- Testing
- Finerenone Oral Tablet
- Where
- 21 sites in Japan
- Volunteers
- 550 people
- Sponsor
- Juntendo University
Heart Failure, Diabetic Kidney Disease
Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study
This study evaluates the safety of finerenone compared with alternate-day spironolactone in patients with heart failure and diabetic kidney disease at increased risk of hyperkalemia.
- Conditions
- Heart Failure, Diabetic Kidney Disease, Hyperkalemia
- Trial name
- SAFE-K (NCT07523867)
- Testing
- Finerenone, Spironolactone (drug)
- Volunteers
- 60 people
- Sponsor
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
This is an observational study in which data from people with chronic kidney disease (CKD) and Type 2 diabetes mellitus (T2D) are collected and studied.
- Trial name
- 22663 (NCT06608212)
- Testing
- Finerenone (Kerendia, BAY948862), Others except finerenone
- Where
- United States
- Volunteers
- 238,038 people
- Sponsor
- Bayer